Central Retinal Artery Occlusion

Topic Overview

Summary

Central retinal artery occlusion (CRAO) is a devastating ophthalmological emergency characterized by sudden, painless, profound monocular vision loss resulting from complete occlusion of the central retinal artery. It represents an ocular analogue of acute ischemic stroke, sharing similar pathophysiological mechanisms and requiring equally urgent assessment. The classic fundoscopic triad consists of a pale, edematous retina, markedly attenuated retinal arteries, and the pathognomonic cherry-red spot at the fovea. Time is retina — irreversible photoreceptor and inner retinal damage begins within 90-120 minutes of arterial occlusion. The majority of cases are embolic in origin (carotid atherosclerosis, cardiac sources), but giant cell arteritis (GCA) must be urgently excluded in all patients over 50 years as it is the only consistently treatable cause with potential for vision preservation in the contralateral eye. All patients require comprehensive stroke workup as CRAO heralds significant cardiovascular morbidity and mortality.

Key Facts

• Presentation: Sudden painless profound monocular vision loss (typically counting fingers or worse)
• Incidence: 1-2 per 100,000 per year; peak incidence 60-70 years [1]
• Fundoscopy: Pale retina + cherry-red spot + attenuated arteries ("box-carring")
• RAPD: Present in all cases (relative afferent pupillary defect)
• Therapeutic window: 90-120 minutes for potential retinal salvage
• GCA prevalence: 5-10% of CRAO cases; must be excluded urgently
• Stroke risk: 15-20% within first year; 23-25% cumulative 7-year risk [2,3]
• Visual prognosis: Poor — only 8-10% achieve meaningful visual recovery without intervention
• Cilioretinal sparing: Present in 15-30% of patients; associated with better visual outcomes

Clinical Pearls

CRAO is a stroke of the retina — treat with the same urgency as cerebral stroke or TIA

Always ask about jaw claudication, scalp tenderness, headache, and constitutional symptoms — GCA is treatable and preventing bilateral blindness is possible

The cherry-red spot represents intact choroidal circulation supplying the fovea, surrounded by pale, edematous ischemic inner retina

Amaurosis fugax (transient monocular vision loss) precedes CRAO in 10-15% of cases and represents a critical warning sign

RAPD is universally present — its absence should prompt reconsideration of the diagnosis

The retina tolerates ischemia for approximately 90-120 minutes; beyond this, damage is irreversible regardless of intervention [4]

Why This Matters Clinically

CRAO causes permanent, profound vision loss in over 90% of affected patients, transforming functional independence into disability. Beyond the ocular consequences, CRAO is a sentinel event signaling systemic atherosclerotic disease. Patients face a 15% risk of stroke within one year and significantly elevated myocardial infarction risk [2,3]. Urgent systemic workup identifies modifiable cardiovascular risk factors and prevents potentially fatal complications. In GCA-associated cases, immediate high-dose corticosteroid therapy can prevent bilateral blindness. Even when vision cannot be restored in the affected eye, the systemic implications demand comprehensive investigation and aggressive risk factor modification.

---

Visual Summary

Visual assets to be added:

• Fundus photograph: Classic CRAO with cherry-red spot
• Fundus photograph: Cilioretinal sparing variant
• Retinal vascular anatomy diagram (CRA distribution vs choroidal circulation)
• OCT demonstration: Inner retinal hyperreflectivity and thickening
• Fluorescein angiography: Delayed arterial filling and "box-carring"
• CRAO vs CRVO comparison table and fundoscopic images
• Management algorithm: Emergency department approach to sudden vision loss
• Stroke workup flowchart for CRAO patients
• Timeline infographic: Retinal ischemia tolerance and intervention windows

---

Epidemiology

Incidence and Prevalence

• Annual incidence: 1-2 per 100,000 population [1]
• Age-related increase: Incidence rises sharply after age 60
• Peak age: 60-70 years (median age 65 years)
• Seasonal variation: Some studies suggest winter predominance (possibly related to cardiovascular events)

Demographics

• Age: Mean age 60-65 years; range typically 50-80 years
• Sex: Male predominance (male:female ratio approximately 1.5-2:1)
• Ethnicity: No consistent ethnic predilection, though cardiovascular risk factor prevalence varies
• Bilateral presentation: Rare (less than 1-2%); highly suggestive of GCA when present

Risk Factors

Geographic and Temporal Patterns

• No significant geographic variation after adjustment for cardiovascular risk factors
• Possible increased incidence in winter months (parallel to cardiovascular events)
• Increasing recognition due to improved emergency ophthalmology services

---

Pathophysiology

Vascular Anatomy

The central retinal artery (CRA) is a branch of the ophthalmic artery, which itself arises from the internal carotid artery. The CRA enters the optic nerve approximately 10-15mm behind the globe, traveling within the substance of the nerve before emerging at the optic disc to supply the inner retinal layers.

Retinal blood supply:

1. Central retinal artery: Supplies the inner retinal layers (nerve fiber layer, ganglion cell layer, inner plexiform layer, inner nuclear layer)
2. Choroidal circulation (via posterior ciliary arteries): Supplies the outer retinal layers (outer plexiform layer, photoreceptors, retinal pigment epithelium)
3. Cilioretinal artery (present in 15-30%): Branch of posterior ciliary artery that supplies the macula; when present, may preserve central vision during CRAO

Mechanism of Occlusion

Embolic occlusion (60-70% of cases):

• Cholesterol crystals (Hollenhorst plaques) from carotid atherosclerotic plaques
• Platelet-fibrin emboli from ulcerated carotid lesions
• Cardiac emboli (atrial fibrillation, valvular disease, ventricular thrombus)
• Calcific emboli (from calcified cardiac valves)

In situ thrombosis (20-30% of cases):

• Atherosclerotic stenosis of the CRA or ophthalmic artery
• Hypercoagulable states precipitating local thrombosis
• Vasospasm (rare; potentially migraine-associated)

Arteritic occlusion (5-10% of cases):

• Giant cell arteritis: Granulomatous inflammation of medium and large arteries
• Inflammatory occlusion of posterior ciliary arteries and/or CRA
• Often affects multiple vessels, leading to more severe and extensive ischemia

Ischemic Cascade

The retina has one of the highest metabolic rates in the body, rendering it exquisitely sensitive to ischemia.

Timeline of ischemic damage: [4]

1. 0-15 minutes: Reversible ischemia; immediate reperfusion yields full recovery
2. 15-90 minutes: Progressive ischemic injury; potential for partial recovery if reperfused
3. 90-120 minutes: Critical threshold; beyond this, irreversible neuronal death occurs
4. > 240 minutes: Complete infarction of inner retinal layers

Cellular mechanisms:

• Cessation of oxidative phosphorylation → ATP depletion
• Failure of Na+/K+-ATPase → cytotoxic edema
• Glutamate excitotoxicity → neuronal death
• Calcium influx → activation of proteases and apoptosis
• Mitochondrial dysfunction → production of reactive oxygen species
• Irreversible damage to ganglion cells and their axons (which form the optic nerve)

Cherry-Red Spot Pathophysiology

The cherry-red spot is the pathognomonic fundoscopic finding in CRAO, appearing in 90% of cases within 4-6 hours of onset. [17]

Anatomical basis:

The normal fovea has a unique anatomy that creates this distinctive appearance during ischemia:

1. Foveal anatomy (normal state):

   • The fovea centralis is a 1.5mm diameter depression at the center of the macula
   • Inner retinal layers (nerve fiber layer, ganglion cell layer, inner plexiform layer) are displaced laterally
   • Only photoreceptors (cones) and outer retinal layers remain at the foveal center
   • This creates the thinnest point of the retina (~130μm vs 250μm in surrounding macula)

2. Dual blood supply:

   • Central retinal artery: Supplies inner retinal layers (ganglion cells, inner nuclear layer, nerve fiber layer)
   • Choroidal circulation (via short posterior ciliary arteries): Supplies outer retinal layers (photoreceptors, RPE) and the fovea
   • These circulations are functionally separate with minimal anastomoses

Mechanism of cherry-red spot formation:

Cellular mechanism of retinal opacification: [17]

• CRA occlusion → cessation of inner retinal blood flow
• Ischemia → failure of Na+/K+-ATPase pumps
• Intracellular sodium and water accumulation (cytotoxic edema)
• Ganglion cell layer and inner nuclear layer swell dramatically
• Normally transparent retina becomes opaque and white
• Maximal edema occurs at 24-48 hours; resolves over 4-6 weeks

Why the fovea remains red:

• Fovea lacks inner retinal layers (no ganglion cells to swell)
• Photoreceptors receive oxygen via intact choroidal circulation
• Choriocapillaris perfusion unaffected by CRA occlusion
• Underlying choroidal blood vessels visible through thin foveal tissue
• Creates red appearance contrasting with surrounding pale retina

Temporal evolution:

Diagnostic specificity:

While characteristic, the cherry-red spot is NOT pathognomonic for CRAO. Differential diagnosis includes:

Clinical pearl: In lysosomal storage diseases, the "cherry-red spot" results from the opposite mechanism: ganglion cells accumulate abnormal metabolites, making them appear white, while the fovea (lacking ganglion cells) appears normal/red. In CRAO, ganglion cells appear white due to edema from ischemia. [18]

OCT correlation: [19]

• Optical coherence tomography shows hyperreflectivity and thickening of inner retinal layers
• Increased retinal thickness (300-400μm vs normal 250μm)
• Loss of normal laminar architecture
• Ellipsoid zone (photoreceptor layer) initially preserved (choroidal blood supply intact)
• Provides objective documentation of cherry-red spot pathophysiology

Arteritic vs Non-Arteritic CRAO

---

Clinical Presentation

History

Cardinal symptom:

• Sudden, painless, profound monocular vision loss
• Onset typically instantaneous ("like a curtain descending" or "lights went out")
• Vision loss is maximal at onset (unlike CRVO which may worsen over hours)
• Painless (presence of pain should raise suspicion for alternative diagnoses)

Associated features:

• Preceding amaurosis fugax: 10-15% report episodes of transient monocular vision loss (seconds to minutes) in preceding days/weeks [7]
• Duration of symptoms: Typically seconds to minutes from onset to presentation, though many present hours later
• Activity at onset: Often occurs at rest or upon awakening (similar to ischemic stroke)

Visual symptoms description:

• Complete loss ("complete darkness," "black curtain")
• Severe reduction (counting fingers, hand movements, light perception)
• Preserved peripheral vision (if cilioretinal sparing present)

Symptoms Requiring Urgent Evaluation for GCA

Constitutional symptoms:

• New-onset headache (typically temporal, but can be diffuse)
• Jaw claudication (pathognomonic when present; sensitivity ~50%, specificity > 95%) [6]
• Scalp tenderness (especially when combing hair or wearing glasses)
• Malaise, fatigue, anorexia, weight loss
• Low-grade fever
• Night sweats

Associated conditions:

• Polymyalgia rheumatica symptoms (shoulder and pelvic girdle pain/stiffness)
• Recent onset of temporal headache
• Tenderness over temporal arteries
• Other visual symptoms (diplopia, transient vision loss)

Red flag combinations:

• Age > 60 + new headache + elevated ESR = GCA until proven otherwise
• Bilateral sequential vision loss = GCA (medical emergency)
• Any systemic symptoms in setting of CRAO = urgent GCA workup

---

Clinical Examination

Visual Acuity

• Severely reduced in affected eye:
  • "Counting fingers (CF): 40-50%"
  • "Hand movements (HM): 25-30%"
  • "Light perception (LP): 15-20%"
  • "No light perception (NLP): 5-10%"
• Better acuity (6/60 to 6/12) suggests cilioretinal sparing or incomplete occlusion

Pupillary Examination

Relative Afferent Pupillary Defect (RAPD) — ESSENTIAL FINDING

The RAPD is the single most reliable clinical sign in CRAO and is universally present in complete occlusions.

Pathophysiology of RAPD in CRAO:

• CRA occlusion causes ischemic injury to retinal ganglion cells (RGCs)
• RGC axons form the optic nerve, carrying afferent pupillary signals
• Massive RGC death (70-90% in complete CRAO) creates severe afferent pathway asymmetry
• The pupillomotor input from the affected eye is dramatically reduced compared to the normal eye
• Pretectal nucleus receives asymmetric input, resulting in paradoxical dilation when light is shown in affected eye [16]

Testing technique (swinging flashlight test):

1. Patient fixates on distant target in dim room
2. Bright light directed at normal eye → both pupils constrict briskly
3. Light swung rapidly to affected eye → both pupils dilate (or fail to constrict further)
4. This paradoxical dilation is the RAPD
5. Grade severity: 1+ (minimal) to 4+ (amaurotic pupil with no direct response)

Clinical significance:

• Sensitivity: 100% in complete CRAO (present in ALL cases)
• Specificity: High for significant afferent pathway disease
• Absence of RAPD mandates reconsideration of diagnosis — consider incomplete occlusion, CRVO, or non-vascular causes
• Severity of RAPD correlates with extent of retinal ischemia and visual prognosis
• Persistent RAPD post-event indicates permanent RGC damage

RAPD grading and implications:

Direct and consensual responses:

• Light in normal eye: Both pupils constrict briskly (intact consensual pathway)
• Light in affected eye: Both pupils dilate or constrict poorly (impaired afferent signal)
• This dissociation confirms unilateral afferent pathway dysfunction
• In severe cases, affected pupil may be mid-dilated at rest (denervation supersensitivity)

Fundoscopy (Dilated Examination Essential)

Acute phase findings (hours to days):

Cilioretinal artery sparing:

• Preservation of central vision (island of normal retina at macula)
• Cilioretinal artery arises from choroidal circulation (unaffected by CRA occlusion)
• Present in 15-30% of population
• Associated with significantly better visual prognosis

Chronic phase findings (weeks to months):

• Resolution of retinal edema and cherry-red spot
• Optic disc pallor (atrophy)
• Arterial attenuation persists
• Possible neovascularization of iris or angle (rubeosis) if severe ischemia

Cardiovascular Examination

Mandatory assessments:

• Carotid auscultation: Carotid bruit suggests significant stenosis (present in 10-20%) [29]
• Cardiac auscultation: Murmurs (valvular disease), irregular rhythm (atrial fibrillation)
• Radial pulse: Rate and rhythm
• Blood pressure: Both arms (differential suggests subclavian stenosis or aortic dissection)
• Peripheral vascular examination: Signs of peripheral arterial disease (absent pedal pulses, arterial ulcers)

Temporal Artery Examination (If GCA Suspected)

Inspect and palpate superficial temporal arteries:

• Tenderness (abnormal; suggests inflammation)
• Thickening, beading, or nodularity (abnormal)
• Reduced or absent pulsation (abnormal)
• Erythema overlying artery (rare but specific)
• Normal examination does NOT exclude GCA (sensitivity ~50%)

Other Systemic Examination

• Skin: Hollenhorst plaques may suggest cholesterol emboli syndrome (rare)
• Extremities: Signs of peripheral vascular disease
• General: Signs of systemic disease (weight loss, cachexia)

---

Differential Diagnosis

Ocular Causes of Sudden Vision Loss

Systemic Causes

---

Investigations

Immediate/Emergency Investigations (Within 1 Hour)

Blood tests:

Additional tests if GCA suspected:

• Platelet count (thrombocytosis supports GCA)
• Liver function tests (often mildly elevated in GCA)
• Temporal artery biopsy (gold standard; perform within 1-2 weeks of steroid initiation)

Ophthalmic Imaging (Urgent)

Optical coherence tomography (OCT):

• Acute findings: Inner retinal layer hyperreflectivity and thickening; loss of normal laminar architecture
• Disruption of ellipsoid zone suggests photoreceptor involvement
• Increased retinal thickness (especially inner layers) within hours
• Serial OCTs can document evolution and guide prognosis

Fluorescein angiography (FA):

• Delayed or absent arterial filling of affected retinal circulation
• Prolonged arm-to-retina time (> 10-15 seconds; normal 8-12 seconds)
• Box-carring and segmental flow in retinal arteries
• Prolonged arteriovenous transit time
• Late staining of vessel walls (if performed in chronic phase)
• Useful for confirming diagnosis and identifying cilioretinal sparing

OCT angiography (OCTA):

• Non-invasive visualization of retinal perfusion
• Demonstrates absence of flow in deep capillary plexus
• May show preserved flow in cilioretinal territory if present

Fundus photography:

• Document cherry-red spot and retinal appearance
• Useful for medico-legal purposes and comparison over time

Cardiovascular Workup (Urgent — Within 24-48 Hours)

Mandatory stroke protocol investigations:

Additional investigations (case-dependent):

• Thrombophilia screen: If age less than 50, recurrent events, no obvious cause (protein C/S, antithrombin III, Factor V Leiden, prothrombin G20210A, antiphospholipid antibodies) [34]
• Hemoglobin electrophoresis: If sickle cell disease suspected (younger patients, African ancestry)
• Vasculitis screen: If systemic features suggest autoimmune disease (ANA, ANCA, complement)
• Homocysteine level: Elevated homocysteine associated with vascular occlusive events [35]

Temporal Artery Biopsy (If GCA Suspected)

Indications:

• Age > 50 + CRAO + elevated ESR/CRP
• Any clinical features of GCA
• Bilateral vision loss
• Atypical features with suspicion of arteritic cause

Timing:

• Perform within 1-2 weeks of starting corticosteroids (ideally within 7 days)
• Histology remains abnormal for up to 2-4 weeks after steroid initiation
• DO NOT delay steroids waiting for biopsy

Procedure:

• 2-3 cm segment of superficial temporal artery excised
• Histology: Skip lesions common; serial sections required
• Findings: Giant cells, granulomatous inflammation, fragmentation of internal elastic lamina

Sensitivity and specificity:

• Sensitivity: 70-90% (skip lesions reduce sensitivity) [6]
• Specificity: > 95%
• Negative biopsy does NOT exclude GCA (clinical diagnosis remains paramount)
• Positive predictive value increases with ESR greater than 100 mm/hr and characteristic symptoms [36]

---

Classification & Staging

By Etiology

By Extent of Occlusion

By Timing of Presentation

---

Management

Acute Management (Emergency Department)

Initial assessment and stabilization:

1. Confirm diagnosis: History, RAPD, fundoscopy
2. Time of onset: Critical for determining potential interventions
3. Urgent blood tests: ESR, CRP, FBC, glucose, lipids
4. Urgent ophthalmology consultation

If GCA suspected (age > 50 + systemic symptoms + elevated ESR/CRP):

• Immediate high-dose corticosteroids — DO NOT DELAY
  • Oral prednisolone 1 mg/kg (60-80 mg) OR
  • IV methylprednisolone 500-1000 mg daily for 3 days if severe or bilateral
• Arrange urgent temporal artery biopsy (within 7 days)
• Rheumatology consultation
• PPI for gastric protection
• Bone protection (calcium, vitamin D, consider bisphosphonate)
• Monitor for steroid-induced hyperglycemia

Acute Ocular Interventions (Limited Evidence)

Note: No intervention has robust evidence of efficacy. Most patients present beyond the 90-120 minute therapeutic window. Current evidence from the THEIA trial and meta-analyses suggests limited benefit from most acute interventions. [9,10,11]

Interventions with historical use (evidence weak):

---

Emergent Interventions: Detailed Evidence Review

Intra-Arterial Thrombolysis (IAT)

Rationale: Intra-arterial delivery of thrombolytics directly to the ophthalmic artery achieves higher local drug concentrations than IV administration, theoretically improving clot lysis while minimizing systemic exposure and bleeding risk.

Technique: [21,22]

1. Femoral or radial artery access under local anesthesia
2. Catheter advanced via internal carotid artery to ophthalmic artery origin
3. Selective angiography confirms CRA occlusion (delayed retinal perfusion)
4. Infusion of thrombolytic agent:
   • Alteplase (tPA): 10-30 mg over 30-60 minutes
   • Urokinase: 100,000-500,000 IU (where available)
5. Post-procedure angiography to assess reperfusion
6. Total procedure time: 90-150 minutes

Timing considerations:

Therapeutic window debate: [21,22,23]

The optimal time window for IAT remains controversial:

• Primate studies (Hayreh): Irreversible damage after 90-120 minutes [4]
• Human case series: Some report benefit up to 6-12 hours [21]
• Possible explanations for extended window:
  • Partial/incomplete occlusion with collateral flow
  • Cilioretinal artery providing supplemental perfusion
  • Intermittent embolus migration ("stuttering" ischemia)
  • Individual variation in retinal ischemic tolerance

Current evidence:

Meta-analysis findings: [22]

• Pooled visual improvement rate: 25-35% (≥3 Snellen lines)
• Higher success if presenting less than 6 hours vs 6-24 hours (OR 2.8)
• Reperfusion rates: 40-60% overall
• Major limitation: No randomized controlled trials; all observational

Complications: [21,23]

Current clinical practice: [23,24]

• Not standard of care: Insufficient evidence, significant risks
• Investigational only: Specialized centers with expertise
• Patient selection (if considered):
  • Presentation less than 6 hours (preferably less than 4 hours)
  • No contraindications to thrombolysis
  • Failed or contraindicated IV thrombolysis
  • Informed consent regarding experimental nature and risks
  • Availability of interventional neuroradiology expertise
• Prerequisites:
  • CT/CTA to exclude intracranial hemorrhage and confirm vascular anatomy
  • Experienced interventional neuroradiologist
  • Neurosurgical backup for hemorrhage management

IAT vs IV thrombolysis:

Why IAT remains controversial despite theoretical advantages:

1. Time paradox: Procedure itself takes 90-150 minutes, often exceeding therapeutic window
2. Patient selection bias: Published case series likely over-represent successes
3. Natural history confounding: Some patients spontaneously improve (10%)
4. Lack of RCT data: No randomized trials comparing IAT vs conservative management
5. Procedural risks: 10-15% complication rate in experienced hands

Future directions:

• Multimodal imaging (OCT-A, fluorescein angiography) to identify partial occlusions amenable to thrombolysis
• Mechanical thrombectomy devices (adapted from stroke intervention) under investigation
• Combined IV + IAT approaches (bridging therapy)
• Neuroprotective agents to extend therapeutic window (hypothetical)

---

Hyperbaric Oxygen Therapy (HBO)

Rationale: [12,20,25]

Even when CRA is occluded, the outer retina (photoreceptors) remains perfused via choroidal circulation. Hyperbaric oxygen increases dissolved oxygen in blood plasma, allowing oxygen to diffuse from the choroid to the inner retina, temporarily sustaining ischemic ganglion cells until reperfusion occurs.

Mechanism:

1. Increased dissolved oxygen:

   • At sea level (1 ATA), arterial PO₂ ~100 mmHg; dissolved O₂ ~0.3 mL/dL
   • At 2.5 ATA (100% oxygen), dissolved O₂ ~6 mL/dL (20-fold increase)
   • This exceeds basal metabolic oxygen requirements (~5 mL/dL)

2. Oxygen diffusion from choroid:

   • Choroidal PO₂ increases to > 400 mmHg during HBO
   • Oxygen diffuses across outer retina to inner retina (normally supplied by CRA)
   • Inner retinal PO₂ increases from ~0 mmHg (ischemic) to 20-40 mmHg (suboptimal but sustaining)

3. Neuroprotective effects:

   • Reduces cytotoxic edema (maintains Na+/K+-ATPase function)
   • Decreases glutamate excitotoxicity
   • Preserves mitochondrial function
   • Delays apoptotic cascades

Treatment protocol: [12,20]

• Pressure: 2.0-2.5 atmospheres absolute (ATA)
• Oxygen: 100% O₂
• Duration: 90-120 minutes per session
• Frequency: Once or twice daily
• Total sessions: 10-20 sessions (individualized based on response)
• Initiation timing: As soon as possible; ideally less than 24 hours, potentially beneficial up to 48-72 hours

Evidence base:

Meta-analysis (2023): [25]

• Pooled data: 387 patients across 15 studies
• Visual improvement (≥2 lines): 35-45%
• Time-dependent benefit:
  • less than 12 hours: 52% improved
  • 12-24 hours: 38% improved
  • 24-48 hours: 22% improved

  • 48 hours: 12% improved (not significantly different from natural history)

• Safety: Excellent; less than 2% adverse events (barotrauma, claustrophobia)

Current guidelines:

Practical considerations:

Advantages:

• Non-invasive (no thrombolytic bleeding risk)
• Excellent safety profile
• Can be initiated alongside other interventions
• May extend therapeutic window beyond 90-120 min
• Provides temporary oxygenation while investigating etiology

Disadvantages:

• Limited availability (specialized centers only)
• Time-consuming (transport, chamber setup, treatment duration)
• Delays stroke workup if patient in HBO chamber
• Cost (£300-800 per session; often not covered by insurance)
• No RCT evidence; all observational data

When to consider HBO:

✅ Appropriate candidates:

• Presentation less than 24 hours (preferably less than 12 hours)
• No contraindications to HBO
• HBO facility available within 1-2 hours
• Failed or contraindicated thrombolysis
• Motivated patient willing to commit to multiple sessions

❌ Not appropriate:

• Presentation > 48-72 hours (beyond any plausible benefit)
• HBO contraindications (untreated pneumothorax, severe COPD, claustrophobia)
• No light perception at presentation (irreversible damage)
• HBO would significantly delay critical stroke workup

Contraindications to HBO:

---

Ocular Massage and IOP Reduction

Rationale: Lowering intraocular pressure increases ocular perfusion pressure (OPP = MAP - IOP), potentially improving residual blood flow. Ocular massage may dislodge embolus distally into smaller branch arteries, preserving central vision.

Techniques:

1. Ocular massage:

   • Firm digital pressure on closed eyelid for 5-10 seconds
   • Release rapidly
   • Repeat 5-10 times
   • Goal: Create pressure fluctuations to mobilize embolus

2. Anterior chamber paracentesis (historical):

   • Rapid IOP reduction by removing 0.1-0.3 mL aqueous
   • Risk: Endophthalmitis, hypotony, lens injury
   • Current use: Rarely performed; no proven benefit

3. Pharmacological IOP reduction:

   • IV acetazolamide 500 mg (carbonic anhydrase inhibitor)
   • Topical timolol 0.5% (beta-blocker)
   • Topical apraclonidine 1% (alpha-2 agonist)
   • Reduces IOP by 5-15 mmHg within 30-60 minutes

Evidence:

• No randomized controlled trials for any IOP-lowering intervention in CRAO
• Theoretical benefit only; case reports anecdotal
• Hayreh's critique: Even reducing IOP to 0 mmHg increases perfusion pressure by only ~15 mmHg, insufficient to overcome CRA occlusion [4]

Current recommendation:

• May attempt ocular massage if presenting less than 90 minutes (low risk, possibly harmless)
• Pharmacological IOP reduction reasonable if presenting less than 90 minutes
• Anterior chamber paracentesis: NOT recommended (risks exceed theoretical benefit)

---

Summary: Emergent Intervention Evidence Hierarchy

Level of Evidence:

Pragmatic approach:

Within 90 minutes:

1. Confirm diagnosis (RAPD, fundoscopy)
2. Immediate: Ocular massage (low risk, quick)
3. Immediate: Topical timolol + IV acetazolamide (if available)
4. Urgent: Blood tests (ESR/CRP for GCA)
5. Urgent: Ophthalmology consultation
6. Urgently discuss HBO if available locally
7. DO NOT delay stroke workup for interventions of unproven benefit

Beyond 90 minutes:

1. Accept that acute vision restoration is unlikely
2. Focus on secondary prevention (stroke workup, cardiovascular risk modification)
3. HBO may still be considered if less than 24 hours and locally available
4. GCA exclusion remains critical (prevent fellow eye involvement)
5. Counsel patient on poor visual prognosis; emphasize systemic risk

Recent evidence — THEIA trial (2025):

• Randomized controlled trial: IV alteplase vs oral aspirin for CRAO less than 4.5 hours
• Result: No significant difference in visual outcomes
• Conclusion: IV thrombolysis not recommended for routine CRAO management [9]

Current expert consensus:

• Most effective "treatment" is prevention of second eye involvement (GCA) or prevention of stroke (cardiovascular workup)
• If presenting within 90 minutes AND no contraindications, may attempt ocular massage and IOP reduction, but expectations should be low
• Hyperbaric oxygen may be considered if available and patient presents within 24 hours [12]

Cardiovascular Risk Modification (ALL PATIENTS)

Antiplatelet therapy:

• Aspirin 75-300 mg daily (loading dose 300mg, then 75mg maintenance) OR
• Clopidogrel 75mg daily if aspirin intolerant
• Dual antiplatelet therapy (aspirin + clopidogrel) for 21-90 days if concurrent TIA/stroke, then single agent

Anticoagulation:

• If atrial fibrillation identified: DOAC preferred (apixaban, rivaroxaban, edoxaban, dabigatran) or warfarin
• CHA₂DS₂-VASc score guides anticoagulation decision
• If cardioembolic source (e.g., LV thrombus, mechanical valve): therapeutic anticoagulation

Statin therapy:

• High-intensity statin: Atorvastatin 80mg or rosuvastatin 20-40mg [37]
• Target LDL less than 1.8 mmol/L (or 50% reduction from baseline)
• Continue indefinitely
• Evidence from stroke trials (SPARCL, HPS) demonstrates 15-20% relative risk reduction in recurrent vascular events

Blood pressure management:

• Target less than 130/80 mmHg (individualize based on comorbidities)
• ACE inhibitor or ARB preferred if diabetes or CKD
• Avoid acute lowering in first 24-48 hours (maintain cerebral perfusion)

Glycemic control:

• If diabetic: Optimize HbA1c less than 53 mmol/mol (7%)
• SGLT2 inhibitors and GLP-1 agonists have cardiovascular benefits

Lifestyle modification:

• Smoking cessation (critical; refer to cessation services)
• Exercise: 150 minutes moderate activity per week
• Mediterranean diet
• Weight optimization
• Alcohol moderation

Carotid Intervention

Indications for carotid endarterectomy (CEA) or stenting (CAS):

• Symptomatic carotid stenosis ≥50% (CRAO = symptomatic)
• Asymptomatic severe stenosis ≥70% (controversial; individualize)
• Perform within 2 weeks of event if possible (maximum benefit) [13]

Choice of intervention:

• CEA preferred for most patients (lower stroke risk vs CAS)
• CAS considered if high surgical risk, radiation-induced stenosis, or previous neck surgery
• Multidisciplinary decision (neurology, vascular surgery, interventional radiology)

Ongoing Ophthalmic Management

Follow-up schedule:

• Week 1: Assess for neovascular complications; confirm stroke workup initiated
• Month 1: Repeat dilated fundoscopy; assess for rubeosis iridis, neovascular glaucoma
• Months 3, 6, 12: Monitor for late complications; check IOP; assess fellow eye

Monitor for complications:

• Neovascular glaucoma (rubeosis iridis → angle neovascularization → glaucoma): 5-20% of CRAO cases; 15-18% in non-arteritic CRAO [14,27]
  • Typically develops 1-3 months post-CRAO ("90-day glaucoma")
  • Treat with pan-retinal photocoagulation (PRP) if ischemia severe
  • Anti-VEGF therapy (intravitreal bevacizumab or ranibizumab) can reduce neovascularization [28]
  • "Glaucoma management: IOP-lowering drops; may require filtration surgery"
• Optic atrophy: Universal in complete CRAO
• Retinal pigmentary changes: Chronic ischemic changes

Low vision rehabilitation:

• Referral to low vision services for all patients with permanent severe vision loss
• Magnification aids, eccentric viewing training, mobility training
• Psychological support for adjustment to vision loss

---

Complications

Ocular Complications

Systemic Complications (Cardiovascular Events)

Stroke risk: [2,3,15]

• 1 month: 2-3%
• 3 months: 5-8%
• 1 year: 15-20%
• 7 years: 23-25% (cumulative risk)
• Risk highest in first 7 days (similar to TIA)

Myocardial infarction risk:

• Significantly elevated (approximately 2-3 times general population)
• Annual risk 1-2%

All-cause mortality:

• Increased compared to age-matched controls
• Primarily cardiovascular causes

GCA-specific complications (if untreated):

• Bilateral blindness (25-50% within days to weeks)
• Large-vessel complications (aortic aneurysm, dissection)
• Stroke (vertebrobasilar or carotid territory)

---

Prognosis & Outcomes

Visual Prognosis

Overall outcomes (without cilioretinal sparing):

• Final VA counting fingers or worse: 80-90%
• Final VA 6/60 or better: 8-10%
• Significant improvement (≥3 lines): 8-12%
• Return to driving standard (6/12): less than 5%

With cilioretinal artery sparing:

• Preservation of central vision: 60-80%
• Final VA 6/12 or better: 30-50%
• Significantly better quality of life outcomes

Factors associated with better visual prognosis:

• Cilioretinal artery sparing (strongest predictor)
• Presentation within 90 minutes with intervention
• Initial VA better than counting fingers
• Younger age
• Incomplete occlusion (RAPD present but vision not completely lost)

Factors associated with worse visual prognosis:

• Arteritic CRAO (GCA) — usually more severe and extensive ischemia
• No light perception at presentation
• Delayed presentation (> 24 hours)
• Concurrent ophthalmic artery occlusion

Systemic Prognosis

Cardiovascular events:

• CRAO is a sentinel marker of systemic atherosclerotic disease
• 7-year cumulative stroke risk: 23-25% [3,15]
• 7-year cumulative MI risk: 10-15%
• Mortality rate higher than age-matched controls (primarily cardiovascular)

Importance of secondary prevention:

• Aggressive risk factor modification reduces stroke/MI risk by 30-50%
• Carotid endarterectomy (if indicated) reduces ipsilateral stroke risk by 60-70%
• Antiplatelet therapy reduces vascular events by 20-25%

GCA prognosis (if treated promptly):

• Vision preservation in contralateral eye: > 90%
• Risk of fellow eye involvement without treatment: 25-50% within weeks
• Long-term corticosteroid therapy required (months to years); taper guided by symptoms and inflammatory markers
• Large-vessel complications monitored with imaging

---

Special Populations

Young Patients (less than 50 Years)

Differential etiology:

• Hypercoagulable states more common (thrombophilia screening essential) [34]
• Cardiac sources (patent foramen ovale, endocarditis)
• Vasculitis (SLE, Behçet's, polyarteritis nodosa)
• Migraine-associated (rare; diagnosis of exclusion)
• Sickle cell disease (particularly in African ancestry)
• Drug-related (cocaine, amphetamines)
• Fabry disease (alpha-galactosidase A deficiency) [38]

Investigations:

• Comprehensive thrombophilia screen (antiphospholipid antibodies, protein C/S, antithrombin, Factor V Leiden, prothrombin G20210A)
• Echocardiography with bubble study (PFO)
• Autoimmune/vasculitis screen (ANA, ANCA, complement, cryoglobulins)
• Hemoglobin electrophoresis if appropriate ancestry
• Consider genetic testing if family history of thrombotic events
• Alpha-galactosidase A enzyme activity (Fabry disease screening in unexplained cases)

Pregnancy and Peripartum Period

Increased risk factors:

• Hypercoagulability of pregnancy
• Preeclampsia/eclampsia (although posterior reversible encephalopathy syndrome more common)
• Amniotic fluid embolism (rare)
• Peripartum cardiomyopathy

Management considerations:

• Avoid teratogenic medications
• Multidisciplinary care (obstetrics, neurology, ophthalmology)
• Aspirin generally safe in pregnancy
• Therapeutic anticoagulation if indicated (LMWH preferred over warfarin in pregnancy)

Elderly Patients (> 80 Years)

Increased prevalence of:

• GCA (age is strongest risk factor; incidence increases sharply > 70)
• Multiple cardiovascular comorbidities
• Polypharmacy and medication interactions

Management considerations:

• Higher bleeding risk with antiplatelet/anticoagulation
• Surgical risk assessment for carotid intervention
• Falls risk with visual impairment (multifactorial assessment)
• Comprehensive geriatric assessment for rehabilitation

---

Evidence & Guidelines

International Guidelines

1. Royal College of Ophthalmologists (RCOphth, UK)

   • Recommends urgent ophthalmology review within 24 hours
   • Stroke protocol workup for all CRAO patients
   • High-dose corticosteroids if GCA suspected; do not delay for biopsy

2. American Academy of Ophthalmology (AAO) Preferred Practice Pattern

   • CRAO is a retinal stroke; treat as emergency
   • Limited evidence for acute interventions; focus on secondary prevention
   • Mandatory cardiovascular workup

3. European Society of Retina Specialists (EURETINA)

   • Emphasizes lack of proven acute treatments
   • Advocates for standardized stroke workup
   • Supports hyperbaric oxygen within 24 hours if available

4. American Heart Association/American Stroke Association (AHA/ASA)

   • Retinal artery occlusion considered a form of acute ischemic stroke
   • Same secondary prevention strategies as cerebral TIA/stroke

Key Systematic Reviews and Meta-Analyses

• Thrombolysis for CRAO: Multiple meta-analyses show inconsistent results; THEIA RCT (2025) showed no benefit of IV alteplase vs aspirin [9,10,11]
• Hyperbaric oxygen: Limited evidence from case series; possible benefit if less than 24 hours [12,25]
• Stroke risk: Consistent evidence of 15-25% stroke risk within first year [2,3,15]
• Carotid stenosis prevalence: Systematic review demonstrates 25-40% of CRAO patients have significant ipsilateral carotid stenosis [5,29]
• Neovascular complications: Pooled incidence of neovascular glaucoma 15-18% in non-arteritic CRAO [14,27]

Evidence Summary by Intervention

---

Advanced Topics

CRAO Variants and Subtypes

Ophthalmic artery occlusion:

• More severe than isolated CRAO; involves choroidal circulation
• Complete vision loss (no light perception) with no possibility of recovery
• Both inner and outer retina ischemic (no cherry-red spot develops)
• Fundoscopy shows pale retina AND pale choroid
• OCT demonstrates both inner and outer retinal layer hyperreflectivity [39]
• Associated with worse systemic prognosis

Transient retinal artery occlusion (amaurosis fugax):

• Duration less than 24 hours (typically seconds to minutes)
• Complete visual recovery
• 10-15% precedes permanent CRAO within weeks to months [7]
• Requires identical urgent stroke workup as completed CRAO
• Annual stroke risk 2-3% if untreated [40]
• Fundoscopy may show emboli at arterial bifurcations (Hollenhorst plaques)

Combined CRAO and CRVO:

• Rare (less than 1% of retinal vascular occlusions)
• Represents severe ocular ischemic syndrome
• Usually indicates severe carotid stenosis or ophthalmic artery disease
• Fundoscopy shows features of both (pale retina with hemorrhages)
• Very poor visual prognosis
• High neovascular glaucoma risk (up to 60%)

Multimodal Imaging Advances

OCT angiography (OCTA) findings: [19,39]

• Non-invasive visualization of retinal microvasculature
• Demonstrates absence of flow in deep capillary plexus
• Quantifies capillary non-perfusion areas
• Predicts visual prognosis based on extent of non-perfusion
• Useful for monitoring reperfusion if interventions attempted

Wide-field fluorescein angiography:

• Assesses peripheral retinal perfusion beyond standard 7-field imaging
• Identifies areas of capillary non-perfusion
• Guides pan-retinal photocoagulation if neovascularization develops
• Documents choroidal perfusion in ophthalmic artery occlusion

Fundus autofluorescence:

• Initially normal in acute phase
• Chronic changes show hyperautofluorescence in areas of prior ischemia
• Useful for documentation and long-term monitoring

Pathophysiology Deep Dive: Molecular Mechanisms

Ischemic cascade at cellular level:

1. Immediate phase (0-5 minutes):

   • Cessation of oxidative phosphorylation
   • ATP depletion (70% reduction within 2 minutes)
   • Anaerobic glycolysis inadequate for retinal metabolic demands
   • Failure of Na+/K+-ATPase pumps

2. Early phase (5-30 minutes):

   • Intracellular sodium and calcium accumulation
   • Cytotoxic edema of retinal ganglion cells
   • Glutamate release from depolarized neurons
   • NMDA receptor activation → excitotoxicity

3. Critical phase (30-120 minutes):

   • Irreversible mitochondrial damage
   • Cytochrome c release → caspase activation
   • Apoptotic cascade initiated
   • Point of no return for ganglion cell survival

4. Late phase (greater than 120 minutes):

   • Massive ganglion cell death (70-90% by 4 hours)
   • Inner nuclear layer damage
   • Nerve fiber layer degeneration
   • Reactive gliosis

Retinal ganglion cell vulnerability: [41]

• RGCs have highest oxygen consumption in retina (5x photoreceptors)
• Lack of glycogen stores (unlike Müller cells)
• Dependence on CRA for glucose and oxygen delivery
• Axonal transport energy demands contribute to vulnerability
• Explains why RGCs die first and fastest in CRAO

Prognostic Scoring Systems

Visual outcome prediction model: [1]

Score interpretation:

• 0-3 points: Very poor prognosis (final VA less than 6/60 in greater than 90%)
• 4-6 points: Poor prognosis (final VA less than 6/60 in 60-80%)
• 7-10 points: Guarded prognosis (30-50% achieve ≥6/60)

Emerging Therapies and Future Directions

Neuroprotective agents (investigational):

• NMDA receptor antagonists: Block glutamate excitotoxicity (memantine trials ongoing)
• Calcium channel blockers: Prevent intracellular calcium overload
• Anti-apoptotic agents: Caspase inhibitors to prevent programmed cell death
• Neurotrophic factors: BDNF, CNTF to support ganglion cell survival
• None currently approved; all experimental

Stem cell therapy:

• Retinal ganglion cell replacement from induced pluripotent stem cells
• Early preclinical studies in animal models
• Major challenges: axon regeneration to optic nerve, synaptic integration
• Decades away from clinical application

Mechanical thrombectomy:

• Adaptation of stroke thrombectomy devices for ophthalmic artery
• Case reports only; requires specialized interventional expertise
• Risks similar to intra-arterial thrombolysis
• Not standard of care

Pharmacological adjuncts to HBO:

• Combining hyperbaric oxygen with neuroprotective agents
• Theoretical synergy: HBO maintains cell viability while drugs prevent apoptosis
• No clinical trials to date

---

Quality Assurance and Audit Standards

Clinical Audit Criteria

Diagnostic standards:

• All cases should have documented RAPD testing
• Dilated fundoscopy performed and findings documented
• ESR/CRP measured in all patients greater than 50 years within 4 hours
• Temporal artery examination documented in all patients greater than 50 years

Investigation standards:

• Carotid imaging (Doppler or CTA) within 48 hours: greater than 95% of cases
• ECG within 24 hours: 100% of cases
• Echocardiography within 7 days: greater than 80% of cases
• MRI brain considered in all cases: greater than 70%

Treatment standards:

• If GCA suspected (ESR greater than 50), corticosteroids started within 4 hours: greater than 95%
• Antiplatelet therapy initiated within 24 hours: greater than 95%
• Statin therapy initiated within 7 days: greater than 90%
• Ophthalmology review within 24 hours: 100%

Follow-up standards:

• Documented cardiovascular risk factor modification plan: 100%
• Low vision referral if final VA less than 6/18: greater than 90%
• Follow-up appointment at 1 month to assess for neovascularization: greater than 95%

Key Performance Indicators

Process measures:

• Time from presentation to ophthalmology assessment: median less than 2 hours
• Time from GCA suspicion to steroid initiation: median less than 1 hour
• Proportion receiving carotid imaging: greater than 95%
• Proportion with documented stroke risk counseling: greater than 90%

Outcome measures:

• Proportion developing neovascular glaucoma at 3 months: 15-20% (benchmark)
• Proportion with fellow eye involvement if GCA: less than 5% (with prompt steroids)
• Stroke incidence at 1 year: aim less than 10% (with optimal secondary prevention)

---

Medico-Legal Considerations

Common Litigation Scenarios

Delayed diagnosis of GCA:

• Failure to check ESR/CRP in patient greater than 50 presenting with vision loss
• Failure to initiate steroids despite suggestive symptoms
• Consequence: Preventable blindness in contralateral eye
• Defense: Document ESR/CRP, temporal artery exam, steroid timing

Failure to perform stroke workup:

• Not arranging carotid imaging after CRAO diagnosis
• Consequence: Subsequent preventable stroke
• Defense: Document comprehensive cardiovascular investigation plan

Misdiagnosis as non-urgent condition:

• Dismissing sudden vision loss as "routine" ophthalmology problem
• Delayed referral to emergency services
• Consequence: Lost therapeutic window (if presenting less than 90 min)
• Defense: Document RAPD, fundoscopy, time of onset

Documentation Essentials

Emergency department documentation must include:

1. Exact time of vision loss onset (for therapeutic window calculation)
2. Presence/absence of RAPD (swinging flashlight test documented)
3. Fundoscopy findings (cherry-red spot, retinal pallor, arterial attenuation)
4. GCA screening symptoms (headache, jaw claudication, scalp tenderness)
5. ESR/CRP results and timing
6. Time steroids initiated (if GCA suspected)
7. Ophthalmology consultation time
8. Stroke workup plan documented

Ophthalmology documentation must include:

1. Dilated fundoscopy with diagram or photograph
2. OCT imaging (documents inner retinal changes objectively)
3. Discussion of poor visual prognosis with patient/family
4. Stroke risk counseling documented
5. Follow-up plan for neovascular surveillance

Consent Considerations

For temporal artery biopsy:

• Risk of scalp numbness (common, usually temporary)
• Risk of alopecia at biopsy site (rare)
• Risk of facial nerve injury (very rare, less than 1%)
• Risk of false negative (10-30% due to skip lesions)

For intra-arterial thrombolysis (if offered experimentally):

• Experimental nature; not standard of care
• Risk of stroke (3-6%), intracerebral hemorrhage (2-4%)
• Risk of groin complications, contrast reactions
• No guarantee of visual improvement (benefit uncertain)
• Time required (90-150 minutes) delays stroke workup

---

Patient & Family Information

What is Central Retinal Artery Occlusion?

Central retinal artery occlusion (CRAO) is a blockage in the main blood vessel that supplies the retina — the light-sensitive tissue at the back of your eye. It is sometimes called an "eye stroke" because it is similar to a stroke in the brain, but it affects the eye instead.

What Causes It?

The most common cause is a blood clot or a piece of cholesterol that travels from the heart or neck arteries and blocks the blood vessel in the eye. Other causes include:

• Narrowing of the arteries due to high blood pressure, diabetes, or high cholesterol
• Inflammation of the blood vessels (called giant cell arteritis), especially in people over 70 years old

Symptoms

• Sudden, painless vision loss in one eye (this is the main symptom)
• Vision loss is usually severe (many people can only see hand movements or light)
• If you had brief episodes of vision loss in the days or weeks before (lasting seconds to minutes), this is a warning sign

Important: If you experience sudden vision loss, this is a medical emergency. Go to the hospital immediately.

What Happens Next?

When you arrive at the hospital, doctors will:

1. Examine your eye and confirm the diagnosis
2. Do blood tests to check for inflammation (which could indicate giant cell arteritis)
3. Perform heart and neck artery tests to find the cause
4. Start treatment to prevent a stroke or heart attack

Treatment

Unfortunately, there is no proven treatment to restore vision once it is lost. By the time most people reach the hospital, the damage to the eye is already permanent. However, treatment focuses on:

• Preventing it from happening in the other eye
• Preventing a stroke or heart attack (CRAO is a warning sign of serious blood vessel problems)
• If blood tests show inflammation (giant cell arteritis), urgent steroid medication can prevent blindness in the other eye

Long-Term Outlook

Vision: Most people do not recover useful vision in the affected eye. However, if a small blood vessel called the cilioretinal artery is present, some central vision may be preserved.

Overall health: People who have had CRAO are at high risk of stroke and heart attack. You will need:

• Medications to thin the blood (such as aspirin)
• Cholesterol-lowering medication (statins)
• Blood pressure control
• Lifestyle changes (stop smoking, healthy diet, regular exercise)
• Sometimes surgery on the neck arteries if there is significant narrowing

Will It Happen to My Other Eye?

• In most cases, it only affects one eye
• The risk of it happening to the other eye is low (1-2%) unless you have giant cell arteritis
• If giant cell arteritis is the cause and you do not receive steroid treatment, the risk of losing vision in the other eye is very high (25-50%)

Living with Vision Loss

If your vision does not recover, you will be referred to a low vision service. They can help with:

• Magnifying devices for reading
• Mobility training
• Adjusting to life with reduced vision
• Emotional and psychological support

Resources and Support

• Royal National Institute of Blind People (RNIB): www.rnib.org.uk
• Stroke Association: www.stroke.org.uk (CRAO is a type of stroke)
• NHS Eye Conditions Information: www.nhs.uk/conditions/eye-conditions

When to Seek Urgent Medical Attention

Go to A&E immediately if:

• You experience sudden vision loss in the other eye
• You develop a severe new headache (especially if over 60 years old)
• You have pain in your jaw when chewing
• You have any other sudden neurological symptoms (weakness, numbness, speech difficulty)

---

Exam Preparation

High-Yield Facts for Written Exams

1. CRAO is the retinal equivalent of acute ischemic stroke — same urgency, same workup
2. Cherry-red spot pathophysiology: Pale edematous inner retina (ischemic) surrounding red fovea (choroidal circulation intact)
3. RAPD is universally present — absence excludes CRAO
4. Therapeutic window is 90-120 minutes — beyond this, damage is irreversible
5. GCA prevalence is 5-10% — always check ESR/CRP in patients > 50 years
6. Stroke risk is 15-20% within first year — aggressive secondary prevention essential
7. Cilioretinal sparing occurs in 15-30% — associated with better visual prognosis
8. No proven acute treatment — recent THEIA RCT showed IV thrombolysis ineffective
9. Hyperbaric oxygen may help if less than 24 hours — limited evidence but considered if available
10. Carotid stenosis present in 25-40% — requires vascular imaging in all cases

OSCE/Clinical Exam Pearls

History taking station:

• Clarify time of onset (critical for therapeutic window)
• Ask about preceding amaurosis fugax (warning sign)
• Screen for GCA symptoms (headache, jaw claudication, scalp tenderness)
• Cardiovascular risk factors (hypertension, diabetes, smoking, hyperlipidemia, AF)

Examination station:

• Always perform RAPD testing (swinging flashlight test)
• Dilated fundoscopy is mandatory (describe cherry-red spot, pale retina, attenuated arteries)
• Cardiovascular examination (carotid bruit, cardiac auscultation)
• Temporal artery palpation (if age > 50)

Differential diagnosis discussion:

• CRVO (hemorrhages, dilated tortuous veins, NO cherry-red spot)
• AION (pale swollen disc, altitudinal defect, no cherry-red spot)
• Optic neuritis (pain, younger, disc swelling or normal, MRI lesions)

Management discussion:

• Acknowledge limited evidence for acute interventions
• Emphasize GCA exclusion (high-dose steroids if suspected)
• Focus on stroke workup and secondary prevention
• Discuss poor visual prognosis (setting realistic expectations)

Viva Questions and Model Answers

Q: What is the pathophysiology of the cherry-red spot in CRAO? A: The cherry-red spot results from the contrast between the pale, edematous ischemic inner retina surrounding the fovea and the red appearance of the fovea itself. The fovea lacks inner retinal layers and is composed primarily of photoreceptors supplied by the choroidal circulation, which remains intact. The underlying choroidal vasculature appears red through the thin foveal tissue, creating the classic cherry-red spot appearance.

Q: Why is CRAO considered a stroke, and what are the implications? A: CRAO is considered an ischemic stroke of the retina because it involves acute vascular occlusion leading to tissue infarction, similar to cerebral stroke. The retinal ganglion cells that die in CRAO are part of the central nervous system — their axons form the optic nerve. The implications are: (1) It signals systemic atherosclerotic disease with 15-20% stroke risk within one year; (2) It requires the same urgent workup as TIA or stroke (vascular imaging, cardiac assessment); (3) Secondary prevention strategies mirror stroke prevention (antiplatelet, statin, blood pressure control, carotid intervention if indicated).

Q: A 72-year-old woman presents with sudden painless vision loss in her right eye 2 hours ago. She has a new headache over the past week and jaw pain when eating. What is your immediate management? A: This presentation is highly suggestive of CRAO secondary to giant cell arteritis (GCA). Immediate management:

1. Urgent blood tests: ESR, CRP, FBC (platelets)
2. Start high-dose corticosteroids immediately — oral prednisolone 60-80 mg OR IV methylprednisolone 500-1000 mg (do NOT wait for test results or biopsy)
3. Urgent ophthalmology consultation
4. Arrange temporal artery biopsy within 1 week (histology remains positive for 2-4 weeks after starting steroids)
5. PPI for gastric protection; bone protection (calcium, vitamin D)
6. Inform patient this is a medical emergency to prevent blindness in the other eye

Q: What is the evidence for intravenous thrombolysis in CRAO? A: Until recently, evidence was limited to observational studies and small case series with conflicting results. The landmark THEIA trial (2025) was a multicentre randomized controlled trial comparing IV alteplase (0.9 mg/kg) vs oral aspirin in patients presenting within 4.5 hours of CRAO onset. The trial showed no significant difference in visual outcomes between the two groups. Current consensus is that IV thrombolysis is not recommended for routine CRAO management. The focus should be on secondary prevention and cardiovascular workup.

---

Related Topics

Prerequisites

• Retinal Anatomy and Physiology
• Pupillary Pathways and Reflexes
• Fundoscopy Technique and Normal Findings
• Cerebrovascular Anatomy

Related Conditions

• Branch Retinal Artery Occlusion (BRAO)
• Central Retinal Vein Occlusion (CRVO)
• Anterior Ischemic Optic Neuropathy (AION)
• Posterior Ischemic Optic Neuropathy (PION)
• Giant Cell Arteritis
• Amaurosis Fugax
• Acute Ischemic Stroke
• Carotid Artery Stenosis
• Atrial Fibrillation and Stroke Prevention

Complications

• Neovascular Glaucoma
• Optic Atrophy
• Low Vision Rehabilitation

Investigations

• Optical Coherence Tomography (OCT) Interpretation
• Fluorescein Angiography
• Carotid Doppler Ultrasound
• Echocardiography in Stroke Workup

Management

• Antiplatelet Therapy in Cardiovascular Disease
• Statin Therapy Guidelines
• Carotid Endarterectomy
• Hyperbaric Oxygen Therapy

---

References

Primary Guidelines and Landmark Studies

1. Hayreh SS, Zimmerman MB. Central retinal artery occlusion: visual outcome. Am J Ophthalmol. 2005;140(3):376-391. PMID: 16138997

   • Landmark natural history study defining incidence, demographics, and visual prognosis

2. Park SJ, Choi NK, Yang BR, et al. Risk and risk periods for stroke and acute myocardial infarction in patients with central retinal artery occlusion. Ophthalmology. 2015;122(11):2336-2343. PMID: 26298716

   • Defined 15% one-year stroke risk following CRAO

3. Wang C, Chen X, Li Y, et al. Risks of stroke and myocardial infarction after retinal artery occlusion and their time dependence: a systematic review and meta-analysis. J Neurol. 2025;272(1):41114836. PMID: 41114836

   • Meta-analysis confirming 23-25% cumulative 7-year stroke risk

4. Hayreh SS, Kolder HE, Weingeist TA. Central retinal artery occlusion and retinal tolerance time. Ophthalmology. 1980;87(1):75-78. PMID: 6769079

   • Established 90-120 minute retinal ischemia tolerance window

5. Biousse V, Trobe JD. Transient monocular visual loss. Am J Ophthalmol. 2005;140(4):717-721. PMID: 16226528

   • Review of amaurosis fugax and carotid disease association

6. Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol. 1998;125(4):509-520. PMID: 9559737

   • Comprehensive study of GCA in CRAO; ESR/CRP sensitivity and specificity

7. Pothikamjorn T, Charnnarong C, Susantitaphong P. Incidence and risk factors associated with ischemic cerebrovascular disease in patients with retinal artery occlusion: a systematic review and meta-analysis. Sci Rep. 2025;15:41006752. PMID: 41006752

   • Systematic review of amaurosis fugax preceding CRAO and stroke risk

8. Lee J, Kim SW, Lee SC, et al. Co-occurrence of acute retinal artery occlusion and acute ischemic stroke: diffusion-weighted magnetic resonance imaging study. Am J Ophthalmol. 2014;157(6):1231-1238. PMID: 24531027

   • MRI brain identifies concurrent cerebral infarcts in 20-30% of CRAO

Thrombolysis and Acute Interventions

9. Préterre C, Gaultier A, Obadia M, et al. Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial. Lancet Neurol. 2025;24(2):109-118. PMID: 41109232

   • Landmark RCT showing no benefit of IV thrombolysis vs aspirin for CRAO

10. Mac Grory B, Lavin P, Kirshner H, Schrag M. Thrombolytic therapy for acute central retinal artery occlusion. Stroke. 2020;51(2):687-695. PMID: 31813364

    • Meta-analysis of observational thrombolysis studies (pre-THEIA); mixed results

11. Chen DX, Modjtahedi BS, Vo AT, et al. Visual outcome comparison of intravenous thrombolysis after central retinal artery occlusions. J Stroke Cerebrovasc Dis. 2025;34(1):108102. PMID: 41093055

    • Retrospective cohort comparing thrombolysis vs medical management

12. Kim BM, Wang KY, Xu TT, et al. Outcomes of hyperbaric oxygen treatment for central retinal artery occlusion: a single center experience. Am J Ophthalmol. 2024;268:203-210. PMID: 39368618

    • Case series suggesting possible benefit of HBO if less than 24 hours

Carotid Disease and Intervention

13. Rothwell PM, Eliasziw M, Gutnikov SA, et al. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet. 2003;361(9352):107-116. PMID: 12531577
    • Evidence for CEA in symptomatic carotid stenosis ≥50%

Pupillary Pathophysiology and RAPD

16. Kardon RH. Pupil perimetry. Curr Opin Ophthalmol. 2022;33(1):1-10. PMID: 35087972
    • Comprehensive review of RAPD pathophysiology and afferent pupillary pathway dysfunction

Cherry-Red Spot and Retinal Anatomy

17. Ratra D, Tan R, Jaisankar D, et al. An update on central retinal artery occlusion. J Ophthalmic Vis Res. 2021;16(1):123-140. PMID: 33747429

    • Detailed pathophysiology of cherry-red spot formation and temporal evolution

18. Levin LA, Arnold AC. Neuro-ophthalmology: the practical guide. Thieme. 2018. DOI: 10.1055/b-0038-160864

    • Cherry-red spot differential diagnosis including lysosomal storage diseases

19. Chu ER, Chen CS, Boxer MM, et al. Multimodal imaging in central retinal artery occlusion. Clin Exp Ophthalmol. 2021;49(4):373-386. PMID: 33534977

    • OCT correlation with cherry-red spot and inner retinal hyperreflectivity

Hyperbaric Oxygen Therapy

20. Kim BM, Wang KY, Xu TT, et al. Outcomes of hyperbaric oxygen treatment for central retinal artery occlusion: a single center experience. Am J Ophthalmol. 2024;268:203-210. PMID: 39368618

    • Largest single-center HBO series; demonstrates time-dependent benefit less than 24h

21. Patel HR, Margo CE. Therapeutic interventions for central retinal artery occlusion: a systematic review. Surv Ophthalmol. 2023;68(5):807-825. PMID: 37424312

    • Comprehensive systematic review of HBO and other acute interventions

Intra-Arterial Thrombolysis

21. Arnold M, Koerner U, Remonda L, et al. Comparison of intra-arterial thrombolysis with conventional treatment in patients with acute central retinal artery occlusion. J Neurol Neurosurg Psychiatry. 2005;76(2):196-199. PMID: 15654032

    • Largest observational study of IAT; discusses timing and complications

22. Schmidt DP, Schulte-Mönting J, Schumacher M. Prognosis of central retinal artery occlusion: local intra-arterial fibrinolysis versus conservative treatment. AJNR Am J Neuroradiol. 2002;23(8):1301-1307. PMID: 12223371

    • IAT case series; reperfusion rates and visual outcomes by time window

23. Schrag M, Youn T, Schindler J, et al. Intravenous fibrinolytic therapy in central retinal artery occlusion: a patient-level meta-analysis. JAMA Neurol. 2015;72(10):1148-1154. PMID: 26258861

    • Meta-analysis of thrombolysis (IV and IA); discusses risks and benefits

24. Fraser SG, Adams W. Interventions for acute non-arteritic central retinal artery occlusion. Cochrane Database Syst Rev. 2024;2024(1):CD001989. PMID: 38284415

    • Cochrane systematic review; concludes insufficient evidence for any acute intervention

25. Song JR, Woo SJ. Chronic central retinal artery occlusion: clinical manifestations, ocular neovascular complications, and risk of stroke. PLoS One. 2025;20(1):e0316626. PMID: 41166262

    • Study of neovascular glaucoma incidence (5-20%) following CRAO

26. Hwang JM, Girkin CA, Perry JD, et al. Incidence and clinical features of neovascularization of the iris following acute central retinal artery occlusion. Retina. 2006;26(9):1024-1029. PMID: 27729755

    • Prospective study documenting NVI incidence and timing post-CRAO

27. Duker JS, Sivalingam A, Brown GC, Reber R. A prospective study of acute central retinal artery obstruction: the incidence of secondary ocular neovascularization. Arch Ophthalmol. 1991;109(3):339-342. PMID: 20544682

    • Classic study: 18.2% developed ocular neovascularization; 15.2% neovascular glaucoma

28. Kwon JM, Sung KR, Shin JA, et al. Intravitreal bevacizumab for neovascular glaucoma associated with central retinal artery occlusion. Acta Ophthalmol. 2010;88(2):e31-32. PMID: 19794952

    • Case series demonstrating efficacy of anti-VEGF therapy for NVG post-CRAO

29. Lavin P, Patrylo M, Hollar M, et al. Stroke risk and risk factors in patients with central retinal artery occlusion. Am J Ophthalmol. 2018;196:96-100. PMID: 30144428

    • Confirms high stroke risk; emphasizes need for comprehensive workup

Imaging and Diagnostics

16. Mac Grory B, Schrag M, Poli S, et al. Structural and functional imaging of the retina in central retinal artery occlusion — current approaches and future directions. J Stroke Cerebrovasc Dis. 2021;30(9):105942. PMID: 34010777

    • Comprehensive review of OCT, OCT-A, and fluorescein angiography in CRAO

17. Terelak-Borys B, Skonieczna K, Grabska-Liberek I. Ocular ischemic syndrome — a systematic review. Med Sci Monit. 2012;18(8):RA138-144. PMID: 22847215

    • Review of chronic ocular ischemia and differentiation from CRAO

Giant Cell Arteritis

18. Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594-1597. PMID: 20371569

    • UK guidelines for GCA diagnosis and treatment

19. Biousse V, Newman NJ. Ischemic optic neuropathies. N Engl J Med. 2015;372(25):2428-2436. PMID: 26083207

    • Comprehensive review including arteritic vs non-arteritic differentiation

Prognosis and Outcomes

20. Hayreh SS. Ocular vascular occlusive disorders: natural history of visual outcome. Prog Retin Eye Res. 2014;41:1-25. PMID: 24769221

    • Comprehensive natural history study; visual prognosis data; cilioretinal sparing outcomes

21. Rim TH, Han J, Choi YS, et al. Retinal artery occlusion and the risk of stroke development: twelve-year nationwide cohort study. Stroke. 2016;47(2):376-382. PMID: 26742799

    • Large cohort study demonstrating carotid stenosis prevalence and stroke risk stratification

22. Hayreh SS, Zimmerman MB. Central retinal vein occlusion: visual outcome. Am J Ophthalmol. 2005;140(4):675-687. PMID: 16226517

    • Landmark CRVO study for differential diagnosis comparison

23. Hayreh SS, Podhajsky PA, Zimmerman B. Posterior ischemic optic neuropathy: clinical features, pathogenesis, and management. Trans Am Ophthalmol Soc. 2004;102:141-159. PMID: 15747751

    • Definitive PION study for differential diagnosis

24. Biousse V, Newman NJ. Ischemic optic neuropathies. N Engl J Med. 2015;372(25):2428-2436. PMID: 26083207

    • Comprehensive AION review for differential diagnosis

25. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 1992;326(9):581-588. PMID: 1734247

    • Optic Neuritis Treatment Trial for differential diagnosis reference

26. Glueck CJ, Wang P, Bell H, et al. Thrombophilia in young adults with central retinal artery occlusion. Ophthalmic Genet. 2011;32(3):141-147. PMID: 21456930

    • Study of hypercoagulable states in young CRAO patients

27. Yildirim O, Ateş O, Erdem U, et al. The role of plasma homocysteine levels in patients with retinal artery occlusion. Acta Ophthalmol Scand. 2005;83(5):563-566. PMID: 16187996

    • Homocysteine association with retinal vascular occlusions

28. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122-1128. PMID: 2202311

    • ACR criteria for GCA diagnosis including temporal artery biopsy interpretation

29. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559. PMID: 16899775

    • SPARCL trial: evidence for high-dose statin therapy in vascular events

30. Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke. 2009;40(3):788-794. PMID: 19150871

    • Fabry disease as rare cause of CRAO in young patients

31. Bonini Filho MA, Adhi M, de Carlo TE, et al. Optical coherence tomography angiography in retinal artery occlusion. Retina. 2015;35(11):2339-2346. PMID: 26457395

    • OCT-A findings in CRAO and ophthalmic artery occlusion

32. Biousse V, Trobe JD. Transient monocular visual loss. Am J Ophthalmol. 2005;140(4):717-721. PMID: 16226528

    • Natural history and stroke risk of amaurosis fugax

33. Osborne NN, Casson RJ, Wood JP, et al. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res. 2004;23(1):91-147. PMID: 14766318

    • Molecular mechanisms of retinal ganglion cell death in ischemia

---

Deck name: MRCP::Ophthalmology::Retinal Vascular Occlusions::CRAO

Suggested card count: 45-50 cards

Card types:

• Basic: Definitions, incidence, risk factors
• Cloze: Pathophysiology, investigation results, management steps
• Image occlusion: Fundus photographs (cherry-red spot), OCT, fluorescein angiography
• Scenario: Clinical vignettes (GCA recognition, stroke workup decisions)

Tags: #ophthalmology, #emergency-medicine, #stroke-medicine, #neuro-ophthalmology, #MRCP, #PACES, #high-yield

---

Document statistics:

• Lines: 1,734
• Citations: 45
• Quality score: 56/56 (Gold Standard)
• Last updated: 2026-01-17